This trial suggests a combo of trastuzumab/tucatinib with chemo may help treat rectal cancer.
- Rectal Adenocarcinoma
- Locally Advanced Rectal Cancer
- Rectal Cancer
- HER2 Positive Rectal Adenocarcinoma
- Colorectal Cancer
1 Primary · 0 Secondary · Reporting Duration: 21 +/- 4 weeks
1 Treatment Group
Participant with Rectal Adenocarcinoma
1 of 1
37 Total Participants · 1 Treatment Group
Primary Treatment: Participant with Rectal Adenocarcinoma · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Can you explain the safety level of those involved in the Participant with Rectal Adenocarcinoma study?
"The safety of those with rectal adenocarcinoma was assessed as a 2 due to the existent data supporting its security, yet lacking evidence for efficacy in this Phase 2 trial." - Anonymous Online Contributor
Are there opportunities for individuals to register at present for this clinical experiment?
"Affirmative, according to data found on clinicaltrials.gov this medical trial is currently open for enrollment and was originally posted December 30th 2022. Last updated January 3rd 2023, the study seeks to recruit 37 patients from 7 distinct sites." - Anonymous Online Contributor
Are there numerous locations in Canada where this research is being conducted?
"This clinical trial is presently open at 7 sites, including Middletown, Montvale and Commack. To reduce the burden of travelling to these locations, it is prudent for potential participants to select a site in close proximity to them." - Anonymous Online Contributor
How many people can partake in this experiment?
"Indeed, according to clinicaltrials.gov, this investigation is actively open for enrollment. This trial was initially published on December 30th 2022 and last edited on January 3rd 2023; it seeks 37 patients from 7 eligible sites." - Anonymous Online Contributor